Alzheimer’s Research Marked by Collaboration and Large-scale Projects, Too

Alzheimer’s Research Marked by Collaboration and Large-scale Projects, Too
A list of more than 80 compounds in clinical trials for Alzheimer’s disease, released by PhRMA, inevitably brings to mind all those that failed previously. But researchers view the new list as a source of hope, increasingly confident a breakthrough may be among them. Alzheimer’s News Today spoke to two Alzheimer's experts about expectations for these current studies. In those interviews, it became clear that — in contrast to what most people assume — collaboration plays an important role in pharmaceutical company work in this field. Academic institutions are also involved in these collaborative efforts. And, in their midst, the Alzheimer’s Association is a driving force, funding collaboration initiatives and offering scientists a platform to come together to discuss research difficulties and progress. What are these initiatives? And how do they help advance potential treatments for Alzheimer’s disease?

Pharma networks

PhRMA is a group of major U.S. pharmaceutical companies that, among other things, works to modernize drug development processes. In the field of Alzheimer’s research, this translates to two major collaborative enterprises — the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the Accelerating Medicines Partnership – Alzheimer’s Disease (AMP-AD). These projects involve more than pharma. Both also engage the Nation
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *